Patent
أعرض في EDS

Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)

التفاصيل البيبلوغرافية
العنوان: Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
Patent Number: 8,143,412
تاريخ النشر: March 27, 2012
Appl. No: 12/989944
Application Filed: June 26, 2009
مستخلص: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
Inventors: Priebe, Waldemar (Houston, TX, US); Skora, Stanislaw (Houston, TX, US); Madden, Timothy (Sugar Land, TX, US); Fokt, Izabela (Houston, TX, US); Conrad, Charles (Spring, TX, US)
Claim: 1. A compound selected from the group consisting of: [chemical expression included]
Claim: 2. A compound having the structural formula: [chemical expression included]
Claim: 3. A compound having the structural formula: [chemical expression included]
Claim: 4. A pharmaceutical composition comprising a compound as recited in claim 2 , together with a pharmaceutically acceptable carrier.
Claim: 5. The pharmaceutical composition comprising as recited in claim 4 , wherein said pharmaceutical composition is a topical pharmaceutical composition.
Claim: 6. A pharmaceutical composition comprising a compound as recited in claim 1 , together with a pharmaceutically acceptable carrier.
Claim: 7. The pharmaceutical composition comprising as recited in claim 6 , wherein said pharmaceutical composition is a topical pharmaceutical composition.
Claim: 8. A pharmaceutical composition comprising a compound as recited in claim 3 , together with a pharmaceutically acceptable carrier.
Claim: 9. The pharmaceutical composition comprising as recited in claim 8 , wherein said pharmaceutical composition is a topical pharmaceutical composition.
Current U.S. Class: 546/330
Patent References Cited: 7745468 June 2010 Priebe et al.
7807719 October 2010 Roifman et al.
2005/0277680 December 2005 Priebe et al.
2006/0058297 March 2006 Roifman et al.
2007/0232668 October 2007 Priebe et al.
2008/0167277 July 2008 Conrad et al.
2009/0163545 June 2009 Goldfarb
2010/0152143 June 2010 Priebe et al.
1212984 March 1966
4330105 March 1993
41-3540 March 1966
41003540 March 1966
WO9905109 February 1999
W/03073999 September 2003
WO03086396 October 2003
WO2005000777 January 2005
WO2005058829 June 2005
WO2005092904 October 2005
WO2006029515 March 2006
2006057824 June 2006
WO2006005782 June 2006
WO2006086422 August 2006
WO2007006143 January 2007
WO2007115269 October 2007
WO2007130523 November 2007
WO2008005954 January 2008
WO2008005954 January 2008
WO2008000794 March 2008
2008079460 July 2008
2008083389 July 2008
WO2008118445 October 2008
WO2008121858 October 2008
WO2009073575 June 2009
2009091506 July 2009
WO2009009150 July 2009
WO2010081158 July 2010
Other References: Silverman, R., “The Organic Chemistry of Drug Design and Drug Action,” 2004, Elsevier, pp. 29-32. cited by examiner
International Preliminary Report on Patentability dated Jan. 20, 2011. cited by other
Horiguchi, A. et al., STAT3 Inhibitor WP1066 As a Novel Therapeutic Agent for Renal Cell Carcinoma, British Journal of Cancer,102(11), 1592-1599CODEN: BJCAAI;ISSN: 0007-0920. (2010). cited by other
Kupferman, Michael, E. et al., Therapeutic Suppression of Constitutive and Inducible JAK\STAT Activation in Head and Neck Squamous Cell Carcinoma, Journal of Experimental Therapeutics and Oncology, 8(2), 117-127 CODEN: JETOFX; ISSN: 1359-4117 (2009). cited by other
Kong, Ling-Yuan, et al., A Novel Phosphorylated STAT3 Inhibitor Enhances T Cell Cytotoxicity Against Melanoma Through Inhibition of Regulatory T Cells , Cancer Immunology Immunotherapy, 58(7), 1023-1032 CODEN:CIIMDN; ISSN: 0340-7004 (2009). cited by other
Kong, Ling-Yuan, et al., A Novel Inhibitor of Signal Transducers and Activators of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells, Clinical Cancer Research, 14(18), 5759-5768 CODEN: CCREF4; ISSN: 1078-0432(2008). cited by other
Verstovsek, Srdan, et al., WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation Clinical Cancer Research (2008), 14(3), 788-796 CODEN: CCREF4; ISSN: 1078-0432(2008). cited by other
Ferrajoli, Alessandra, et al., WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells, Cancer Research, 67(23), 11291-11299 CODEN: CNREA8; ISSN: 0008-5472(2007). cited by other
Hussain, S. Farzana, et al., A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients, Cancer Research, 67(20), 9630- 9636 CODEN: CNREA8; ISSN: 0008-5472 (2007). cited by other
Bartholomeusz, Geoffrey, et al., Degrasyn Activates Proteasomal-Dependent Degradation of c-Myc, Cancer Research, 67(8), 3912-3918 CODEN: CNREA8; ISSN: 0008-5472 (2007). cited by other
Iwamaru, A., et al., A Novel Inhibitor of the STAT3 Pathway Induces Apoptosis in Malignant Glioma Cells Both in Vitro and in Vivo, Oncogene, 26(17), 2435-2444 CODEN: ONCNES; ISSN: 0950-9232(2007). cited by other
Schepetkin, Igor A., et al., Novel Small-Molecule Inhibitors of Anthrax Lethal Factor Identified by High-Throughput Screening, Journal of Medicinal Chemistry, 49(17), 5232-5244 CODEN: JMCMAR; ISSN: 0022-2623 (2006). cited by other
Duque, J., et al., Structure of N-benzyl-[2-cyano-3-(2′- furyl)acrylamide], Revista CENIC, Ciencias Quimicas, 27(1-2-3), 25-29 CODEN: RCCQER; ISSN: 1015-8553 (1996). cited by other
Hernandez, Ramon, et al., 2-Cyano-N-furfuryl-3-(2-furyl)acrylamide, Acta Crystallographica, Section C: Crystal Structure Communications, C52(1), 203-5 CODEN: ACSCEE; ISSN: 0108-2701 (1996). cited by other
Pomes, R., et al., Structure of N-(2-furfuryl)-2-cyano-3-(5-nitro-2-furyl)acrylamide, Anales de la Asociacion Quimica Argentina, 82(4), 249-55 CODEN: AAQAAE; ISSN: 0365-0375 (1994). cited by other
Durruthy, O., et al., Structure of N-(2-furylmethyl)-alpha-cyano-2-furanacrylamide, Acta Crystallographica, Section C: Crystal Structure Communications, C49(3), 558-9 CODEN: ACSCEE; ISSN: 0108-2701(1993). cited by other
Saikachi, Haruo, et al., Synthesis of furan derivatives. XVIII. 2-Cyano-3(5-nitro-2-furyl)acrylamides and esters, Chem. & Pharm. Bull. (Tokyo), 7, 453-6 (1959). cited by other
Darnell, J.E. jr. , Validating Stat3 in Cancer Therapy, Nature Medicine, 595-596, vol. 11, No. 6, Jun. 2005. cited by other
Heinrich, P.C., et al., Interleukin-6-Type Cytokine Signalling Through the GP130/Jak/STAT Pathway1 , Biochem ,J. 334, 297-314, (1998). cited by other
Seidel. H. M., et al., Pharmaceutical Intervention in the JAK/STAT Signaling Pathway, Oncogene, 19, 2645-2656, (2000). cited by other
Liu, H., et al., Immunohistochemical Localization of Activated Stat3 and hTERT Protein in Psoriasis Vulgaris, Eur J Dermatol , 16(2): 205-6, (2006). cited by other
Trajkovski, T., STAT3-A Promising Molecular Target for Cancer Therapy, University of Toronto Medical Journal, 16, vol. 83 2005 p. 16. cited by other
Pardanani, A., JAK2 Inhibitor Therapy in Myeloproliferative Disorders : Rationale, Preclinical Studies ans Ongoing Clinical Trials, Leukemia , 22, 23-30, (2008). cited by other
Yu, Hua, et al., The Stats of Cancer—New Molecular Targets Come of Age, Naure Reviews, vol. 4, 97-104, Feb. 2004. cited by other
Tefferi, A., et al., JAK2 in Myeloproliferative Disorders is Not Just Another Kinase, Cell Cycle, 4:8, 1053-1056, Aug. 2005. cited by other
Levy, D.E., et al., What Does Stat3 Do? The Journal of Clinical Investigation, vol. 109, No. 9, May 2002. cited by other
Nikitakis, N. G., et al., Targeting the STAT Pathway in Head and Neck Cancer: Recent Advances and Future Prospects, Current Cancer Drug Targets, 4, 637-651, (2004). cited by other
Sun, J., et al., Cucurbitacin Q: A Selective STAT3 Activation Inhibitor with Potent Antitumor Activity, Oncogene 24, 3236-3245 (2005). cited by other
Rahaman, S.O., et al., Inhibition of Constitutively Active Stat3 Suppresses Proliferation and Induces Apoptosis in Glioblastoma Multiforme Cells, Oncogene, 21, 8404-8413, (2002). cited by other
Xie, T., et al., Stat3 Activation Regulates the Expression of Matrix Metalloproteinase-2 and Tumor Invasion and Metastasis, Oncogene , 23, 3550-3560, (2004). cited by other
Huang, S., Regulation of Metastases by Signal Transducer and Activator of Transcription 3 Signaling Pathway: Clinical Implications, Clin Cancer Res 2007, 13(5) 1362-1366, Mar. 1, 2007. cited by other
Xie, T., et al., Activation of Stat3 in Human Melanoma Promotes Brain Metastasis, Cancer Res 2006, 66:(6), 3188-3196, Mar. 15, 2006. cited by other
Levy, D.E., et al., STAT3: A Multifacted Oncogene ,PNAS, vol. 103, No. 27, 10151-10152, Jul. 5, 2006. cited by other
Kisseleva, T., et al., Signaling Through the JAK/STAT Pathway, Recent Advances and Future Challenges, Gene 285: 1-24 (2002). cited by other
Chen, X., et al., Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA, Cell 93: 827-839 (1998). cited by other
Song, J.I., et al., STAT Signaling in Head and Neck Cancer, Oncogene, 19: 2489-2495, (2000). cited by other
Kijima, T. et al., STAT3 Activation Abrogates Growth Factor Dependence and Contributes to Head and Neck Squamous Cell Carcinoma Tumor Growth in Vivo, Cell Growth Differ, 13: 355-362, (2002). cited by other
Song, L. et al., Activation of Stat3 by Receptor Tyrosine Kinases and Cytokines Regulates Survival in Human Non-Small Cell Carcinoma Cells, Oncogene, 22: 4150-4165, (2003). cited by other
Gadina, M., et al., Signaling by Type I and Type II Cytokine Receptors: Ten Years After, Curr. Opin. Immunol. 13:363, (2001). cited by other
Horvath, C.M. The Jak-STAT Pathway Stimulated by Interferon Gamma, Science, STKE, 260:tr8, (2004). cited by other
Lai, S.Y., et al., Erythropoietin-Mediated Activation of JAK-STAT Signaling Contributes to Cellular Invasion in Head and Neck Squamous Cell Carcinoma, Oncogene, 24: 4442-4449, (2005). cited by other
Siavash, H., et al., Abrogation of IL-6-Mediated JAK Signalling by the Cyclopentenone Prostaglandin 15d-PGJ(2) in Oral Squamous Carcinoma Cells, Br J Cancer, 91: 1074-1080, (2004). cited by other
Quadros, M.R., et al., Complex Regulation of Signal Transducers and Activators of Transcription 3 Activation in Normal and Malignant Keratinocytes, Cancer Res, 64 :3934-3939,(2004). cited by other
Hebenstreit D. et al., JAK/STAT-Dependent Gene Regulation by Cytokines, Drug News Perspect. vol. 18 (4), pp. 243-249(2005). cited by other
Boulton, TG, Zhong, Z, Wen, Z, Darnell, Jr, JE, Stahl, N, and Yancopoulos, GD, STAT3 Activation by Cytokines Utilizing gp130 and Related Transducers Involves a Secondary Modification Requiring an H7-Sensitive Kinase Proc Natl Acad Sci U S A. 92(15): 6915-6919 (1995). cited by other
Yuan ZL et al., Central Role of the Threonine Residue within the p—1 Loop of Receptor Tyrosine Kinase in STAT3 Constitutive Phosphorylation in Metastatic Cancer Cells Mol. Cell Biol. vol. 24 (21), pp. 9390-9400. (2004). cited by other
Silva C.M. Role of Stats as Downstream Signal Transducers in Src Family Kinase-Mediated Tumorigenesis Oncogene vol. 23 (48), pp. 8017-8023. (2004). cited by other
O'shea, J. J.et al., A New Modality for Immunosuppression: Targeting the JAK/STAT Pathway, Nature Rev. Drug Disc. (3): 555-564(2004). cited by other
Hellgren, G.,et al., The Growth Hormone Receptor Associates with Jak1, Jak2 and Tyk2 in Human Liver, Growth Horm. IGF Res. 9(3):212-8 (1999). cited by other
Krebs, L. et al. SOCS Proteins: Negative Regulators of Cytokine Signaling Stem Cells vol. 19, pp. 378-387 (2001). cited by other
Shuai, K Regulation of Cytokine Signaling Pathways by PIAS Proteins vol. 16 (2), pp. 196-202. (2006). cited by other
Leaman, D. W. et al., Roles of JAKs in Activation of STATs and Stimulation of c-fos Gene Expression by Epidermal Growth Factor, Mol Cell Biol. 16(1): 369-375(1996). cited by other
Assistant Examiner: Reese, Heidi
Primary Examiner: Andres, Janet
Attorney, Agent or Firm: Nielsen IP Law LLC
رقم الانضمام: edspgr.08143412
قاعدة البيانات: USPTO Patent Grants
الوصف
الوصف غير متاح.